Pricing Log in Create free account
Saturday 17 October 2026 Export LAB’s income statement to Excel — free account

Standard BioTools Inc.

LAB Healthcare Medical Devices

In the quarter to June 2026, revenue fell 7.62%, EPS grew 22.2%, free cash flow grew 52.8% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.63 0.03 −4.55%
Market cap
$258.5M
P/E
2.9×
Fwd P/E
−11.5×
Dividend yield
—
F-score
4/9
Altman Z
−0.82
Beneish M
−2.93
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 14.44
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 4 1 — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 3.66%

Capital & Financial Ratios $m

Market Cap 258.47
Revenue 84.60
Net Income 84.91
Free Cash Flow (82.58)
Net Debt (476.42)
Current Ratio 9.10 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 2.86
Fwd P/E (11.50) (negative: loss-making)
P/S ratio 2.91
P/B ratio 0.46
Past 5Y EPS Growth —
This Y EPS Growth 33.33% (at or above 15%: strong)
Next Y EPS Growth (60.00%) (below 0%: weak)
Next Y revenue growth (3.32%) (below 0%: weak)
Next 5Y EPS Growth 2.27%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −2.7×, against a ten-year median of 2.8×; over the ten years it ranged from −2.7× in 2026 to 6.7× in 2019.
P/S against its own 10 years 58.61%
10-year low 10-year high
P/B against its own 10 years 0.09%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 115 293 188 477
Receivables 20 15 13 16
Inventory 21 21 20 17
Other — 43 228 —
158 376 454 517
2023 2024 2025 Q'26
Payables 9 5 5 10
ST’ Debt 5 — — —
Other — 21 26 —
109 66 108 57

Compound Annual Growth %

10y 5y 3y
Sales (2.92%) (9.19%) (4.49%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 13.96% 25.00% 22.68%

Revenue $m

Mar Jun Sep Dec Year
’26 21 20 — — —
’25 20 22 20 24 85
’24 46 22 22 1 91
’23 25 28 25 28 106
’22 27 19 26 27 98
’21 33 31 29 38 131
’20 28 26 40 45 138
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (47) (10) — — —
’25 (30) (21) (22) (1) (74)
’24 (62) (39) (28) (14) (143)
’23 (8) (9) (11) (14) (43)
’22 (16) (30) (25) (19) (89)
’21 (13) (15) (9) (7) (44)
’20 (4) (3) (5) (4) (15)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (47) (11) — — —
’25 (35) (23) (23) (2) (83)
’24 (63) (41) (30) (17) (152)
’23 (9) (10) (12) (14) (46)
’22 (16) (31) (26) (20) (93)
’21 (20) (19) (11) (7) (57)
’20 (5) (3) (5) (14) (28)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.33 (0.07) — — —
’25 (0.07) (0.09) (0.09) 0.05 (0.20)
’24 (0.27) (0.12) (0.07) (0.09) (0.52)
’23 (0.21) (0.22) (0.27) (0.25) (0.94)
’22 (0.99) (0.82) (0.37) (0.26) (2.43)
’21 (0.25) (0.23) (0.18) (0.12) (0.78)
’20 (0.23) (0.18) (0.08) (0.24) (0.74)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 4.31 2.52 4.65 2.12 1.17 3.59 0.92 1.16 1.21 0.92

Analyst estimates 2026–2028

Powerpack
High 11.05 8.69 9.08 14.90 12.45 7.51 4.23 3.16 3.04 2.14
People
People Employees 589 505 535 566 627 615 523 539 818 389
Revenue/emp, $m 0.18 0.20 0.21 0.21 0.22 0.21 0.19 0.20 0.11 0.22
Income, $m
Income, $m Revenue 104 102 113 117 138 131 98 106 91 85
Gross margin, % 55.95 50.99 54.57 54.83 60.32 53.13 37.83 47.44 49.32 49.86
EBT (80) (64) (61) (67) (54) (64) (193) (74) (90) (97)
EBT margin, % (76.76) (62.59) (54.37) (56.89) (39.16) (48.75) (196.97) (69.78) (99.33) (113.33)
Net income (76) (61) (59) (65) (53) (59) (190) (75) (139) (75)
Depreciation 18 19 25 18 18 16 14 14 9 8
Per share, $
Per share, $ Revenue 3.60 3.09 2.85 1.76 1.92 1.72 1.25 1.34 0.26 0.22
Earnings (2.62) (1.84) (1.49) (0.97) (0.74) (0.78) (2.43) (0.94) (0.52) (0.20)
Cash flow (1.35) (0.73) (0.64) (0.53) (0.21) (0.58) (1.14) (0.55) (0.41) (0.19)
Capex (0.17) (0.05) (0.01) (0.04) (0.18) (0.17) (0.05) (0.04) (0.02) (0.02)
Free cash flow (1.52) (0.78) (0.64) (0.57) (0.39) (0.76) (1.19) (0.58) (0.43) (0.22)
Book value 1.84 0.94 1.82 2.30 1.93 1.25 2.93 2.06 1.34 1.11
Shares, m 29 33 40 67 72 76 78 79 353 382
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 2.11 2.02 3.03 1.98 3.13 2.28 1.04 1.65 6.79 5.72
P/B 4.14 6.64 4.74 1.51 3.11 3.14 0.00 0.00 1.31 1.15
EV/Sales 3.41 3.31 3.70 1.96 3.05 2.60 0.01 0.66 3.63 3.59
EV/FCF (6.99) (10.46) (13.01) (5.17) (12.12) (5.31) (0.01) (1.32) (2.09) (3.43)
Cash, $m
Cash, $m Operating cash flow (39) (24) (25) (35) (15) (44) (89) (43) (143) (74)
Capex (5) (2) 0 (3) (13) (13) (4) (3) (8) (8)
Free cash flow (44) (26) (26) (38) (28) (57) (93) (46) (152) (83)
Balance, $m
Balance, $m Working capital 67 61 90 63 63 22 165 49 310 346
Total debt 195 195 172 56 57 71 65 9 0 0
Net debt 136 132 77 (3) (11) 43 (101) (106) (293) (187)
Shareholders’ equity 53 31 72 154 139 95 230 163 472 424
Returns, %
Returns, % ROA (22.47) (20.39) (19.97) (22.79) (17.99) (19.75) (57.13) (20.93) (39.53) (12.69)
ROIC (24.23) (22.37) (20.23) (21.51) (24.97) (30.73) (56.35) (83.57) (44.48) (29.07)
ROE (90.39) (143.84) (114.53) (57.41) (36.23) (50.71) (2,895.83) 65.05 (114.25) (16.72)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Standard BioTools Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CLPT ClearPoint Neuro, Inc. $294.1M — (loss-making) — (loss-making) +18.07% (above 0%: growing) n/m −173.51% (below 0%: shrinking) 61.67% (94.15%) Compare
QSI Quantum-Si Incorporated $286.7M — (loss-making) — (loss-making) −41.79% (below 0%: shrinking) n/m +9.75% (above 0%: growing) 50.00% (7,450.29%) Compare
INFU InfuSystems Holdings, Inc. $277.2M 31.7× 21.7× +2.59% (above 0%: growing) +33.33% (above 0%: growing) −66.54% (below 0%: shrinking) 57.98% 11.24% Compare
TMCI Treace Medical Concepts, Inc. $267.9M — (loss-making) — (loss-making) −4.24% (below 0%: shrinking) n/m +11.74% (above 0%: growing) 78.47% (32.96%) Compare
CATX Perspective Therapeutics, Inc. $267.1M — (loss-making) — (loss-making) −72.07% (below 0%: shrinking) n/m −66.09% (below 0%: shrinking) 100.00% (36,120.99%) Compare
LAB Standard BioTools Inc. $258.5M 2.9× — (loss-making) −7.62% (below 0%: shrinking) n/m +52.76% (above 0%: growing) 52.40% (126.28%)
TLSI TriSalus Life Sciences, Inc. $240.1M — (loss-making) — (loss-making) +1.73% (above 0%: growing) n/m −41.29% (below 0%: shrinking) 86.78% (86.03%) Compare
ELMD Electromed, Inc. $232.3M 20.0× 25.5× +11.64% (above 0%: growing) +57.69% (above 0%: growing) −25.15% (below 0%: shrinking) 78.71% 19.70% Compare
PROF Profound Medical $230.5M — (loss-making) — (loss-making) +12.30% (above 0%: growing) n/m +17.51% (above 0%: growing) 78.41% (445.67%) Compare
Median of peers $267.5M — — +2.16% — −33.22% 78.44% (90.09%)

All 149 Medical Devices stocks →

Standard BioTools Inc. (LAB) key facts

  • Standard BioTools Inc. (LAB) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, LAB traded at $0.63, a market capitalization of $258.5 million.
  • Return on equity was −16.7% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −0.82 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Standard BioTools Inc. (LAB) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/LAB · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com